AstraZeneca's Competitors, Revenue, Number of Employees, Funding and Acquisitions

AstraZeneca develops pharmaceutical solutions for cancer, cardiovascular, gastrointestinal, infection, neuroscience, res... Read more

Annual Revenue

Employees

Pascal Soriot's photo - CEO of AstraZeneca

CEO

Pascal Soriot

CEO Approval Rating

72/100

OVERVIEW

Founded:

1999

Headquarters:

CambridgeEngland

Status:

PublicIndependent Company of NYSEAZN

Industry Sector:

Pharmaceuticals

SIC Code:

Top Competitors or Alternatives

Missing a competitor? Contribute!

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Pfizer a competitor of AstraZeneca?

Want more news like this in your inbox? Get access for free

Competitive Analysis

TOP COMPETITORS OR ALTERNATIVES

Amgen has been one of AstraZeneca's top competitors. Amgen is a Public company that was founded in 1980 in Thousand Oaks, California. Amgen operates in the Biotechnology industry. Compared to AstraZeneca, Amgen has 38,700 fewer employees.

Genentech is seen as one of AstraZeneca's biggest rivals. Genentech is a Private company that was founded in South San Francisco, California in 1976. Like AstraZeneca, Genentech also competes in the Pharmaceuticals sector. Genentech has 44,983 fewer employees vs. AstraZeneca.

TEVA Pharmaceuticals is perceived as one of AstraZeneca's biggest rivals. TEVA Pharmaceuticals was founded in Petach Tikva, Center District} in 1901. Like AstraZeneca, TEVA Pharmaceuticals also operates in the Pharmaceuticals sector. Compared to AstraZeneca, TEVA Pharmaceuticals generates $4.2B less revenue.

RANK

COMPANY

LEADERSHIP

CEO SCORE

EMPLOYEES

TOTAL FUNDING

REVENUE

Pascal Soriot

CEO

- -
59,700
$0
$21.9B
1

Robert A. Bradway

Chairman & CEO

67/100
19,200
$19M
$23.6B
2

Alexander Hardy

CEO

47/100
14,717
$100M
$18.3B
3

Kaare Schultz

President & CEO

75/100
42,535
$5.5B
$17.7B
4

Emma Walmsley

CEO

71/100
99,827
- -
$39.4B
5

Vasant Narasimhan

CEO

81/100
118,393
- -
$50.3B
6

Albert Bourla

CEO

60/100
92,400
- -
$53.7B
7

Miles D. White

Chairman & CEO

58/100
103,000
$6.9M
$30.9B
8

Kenneth C. Frazier

Chairman & CEO

59/100
69,000
- -
$44.4B
9

Alex Gorsky

Chairman & CEO

66/100
135,100
- -
$81.3B
10

Giovanni Caforio

Chairman & CEO

74/100
23,300
- -
$23.9B

Quarterly and Annual Revenue

Coming soon for AstraZeneca!

Annual Revenue

$21.9B

AstraZeneca's revenue is the ranked 9th among it's top 10 competitors. The top 10 competitors average 36.9B.

Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Acerta Pharma

Dec 2015

Source »
$4B
Acerta Pharma discovers and develops drugs for oncology and autoimmune diseases.
ZS Pharma, Inc.

Nov 2015

Source »
$2.7B
ZS Pharma develops and commercializes non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases.

-

-

Feb 2015

Source »
$600M
-
Pearl Therapeutics, Inc.

Jun 2013

Source »
undisclosed
Pearl Therapeutics focuses on developing products for the treatment of prevalent respiratory diseases and chronic obstructive pulmonary diseases.
Ardea, Inc.

Apr 2012

Source »
$126B
-

These are all the companies that AstraZeneca has acquired. AstraZeneca has acquired 7 companies and its latest acquisition was Acerta Pharma in Dec 2015. Acerta Pharma discovers and develops drugs for oncology and autoimmune diseases.

Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Innate Pharma is a pharmaceutical company that researches and develops therapeutic antibodies for the treatment of cancer and inflammatory diseases.
$71.9M
Oct 22, 2018
Equity
Nov 01, 2006
PhaseBio is a biopharmaceutical firm that researches and develops novel therapeutics for the treatment of orphan diseases.
$34M
Sep 04, 2018
Series D
Oct 27, 2018
Rani Therapeutics is a developer of pills for the oral delivery of peptides, proteins and antibodies to the patients with chronic diseases.
$53M
Feb 07, 2018
Equity
-
PhaseBio is a biopharmaceutical firm that researches and develops novel therapeutics for the treatment of orphan diseases.
$1.5M
Nov 29, 2017
Convertible Note
Oct 27, 2018
ADC Therapeutics develops proprietary antibody-drug conjugates for the treatment of solid and hematological cancers.
$200M
Oct 22, 2017
Series E
-

These are all the companies that AstraZeneca has invested in. AstraZeneca has invested 7 companies and its latest investment was Acerta Pharma in Dec 2015. Acerta Pharma discovers and develops drugs for oncology and autoimmune diseases.

AstraZeneca News

October 15, 2019Biospectrum Asia

ImaginAb inks pact with three global pharma companies

The collaborators will help guide a current ImaginAb-sponsored clinical trial that aims to evaluate t... See more »
October 15, 2019Medical Device Network

ImaginAb partners with pharma giants on CD8 ImmunoPET tech

Clinical stage immuno-oncology imaging company ImaginAb has announced the signing of a multi-party co... See more »
October 15, 2019DirectorsTalk Interviews

AstraZeneca plc 3.5% Potential Decrease Indicated by Jefferies International

AstraZeneca plc using EPIC/TICKER code (LON:AZN) has had its stock rating noted as 'Reiterates' with ... See more »
October 15, 2019PMLiVE

Leading AstraZeneca's return to growth in Europe

PME talks to Iskra Reic, the company's head of Europe and Canada... See more »
October 14, 2019FiercePharma

AZ got past FluMist's efficacy woes, but now it's plagued by production problems

Officials recommended against AstraZeneca's FluMist for two years, but now the company has run into a... See more »
October 14, 2019BioPortfolio

GSK and AZ on continuous manufacturing platform grand challenge

A consortium between CPI and the University of Strathclyde aims to create a direct compression platfo... See more »
October 10, 2019Delaware Business Now

AstraZeneca drug trial shows longer survival times for patients with a type of advanced lung cancer

AstraZeneca reported a late-stage trial shows lung cancer drug Tagrisso showed longer survival timefr... See more »

AstraZeneca Press Releases

August 15, 2019PRWeb

Providing Educational Inspiration in STEM Based Subjects

Find out how Adam Equipment's TBB mechanical triple beam balance helped approximately 4,000 year 5 an... See more »
August 1, 2019StreetInsider

Learning Undefeated Debuts New Drop Anywhere Labs, an Innovative STEM Education Concept Using Modified Shipping Containers

More than $2.45 Million Raised to Bring New Mobile STEM Labs to 300 Percent More Middle and High Scho... See more »
June 20, 2019StreetInsider

A Human Monoclonal Antibody Directed Against Programmed Death-Ligand 1 (PD-L1)

The "Imfinzi" drug pipelines has been added to ResearchAndMarkets.com's offering. Imfinzi (durvalumab... See more »
May 29, 2019GlobalNewswire

American Kidney Fund and AstraZeneca Announce Campaign to Expand Education and Awareness of Hyperkalemia in Patients with Kidney Disease

Campaign, web content will seek to increase understanding of the importance oflong-term control of po... See more »
May 20, 2019Business Wire

FASENRA® (benralizumab) reduces oral corticosteroid use and maintains long-term efficacy and safety profile in severe eosinophilic asthma

WILMINGTON, Del.--(BUSINESS WIRE)--A new integrated analysis of Phase III data for FASENRA® (benraliz... See more »
April 11, 2019PRcom

Exclusive Speaker Interviews with AstraZeneca, Ensysce Biosciences & Metys Pharmaceuticals Released for Pain Therapeutics 2019

SMi reports: Metys Pharmaceuticals, Ensysce Biosciences & AstraZeneca will be speaking and presenting... See more »
April 4, 2019StreetInsider

Myriad, AstraZeneca and Merck Expand Companion Diagnostic Partnership

SALT LAKE CITY, April 04, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in ... See more »

AstraZeneca Videos

Social Statistics

Headquarters

1 Francis Crick Avenue Cambridge Biomedical Campus

Cambridge, EnglandCB2 0RE

44-20-7604-8000

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

AstraZeneca UK Limited (LON: AZN) develops pharmaceutical solutions for cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. It discovers new medicines that are designed to improve the health and quality of ...

CEO

AstraZeneca's CEO, Pascal Soriot, currently has an approval rating of 72%. AstraZeneca's primary competitors are Amgen, Genentech & TEVA Pharmaceuticals.

Website

astrazeneca.com

Frequently Asked Questions about AstraZeneca

  1. When was AstraZeneca founded?

    AstraZeneca was founded in 1999
  2. Who is AstraZeneca's CEO?

    AstraZeneca's CEO is Pascal Soriot
  3. How much revenue does AstraZeneca generate?

    AstraZeneca generates $21.9B in revenue
  4. How much funding does AstraZeneca have?

    AstraZeneca has historically raised $0 in funding
  5. Where is AstraZeneca's headquarters?

    AstraZeneca's headquarters is in Cambridge England, GB
  1. How many employees does AstraZeneca have?

    AstraZeneca has 59,700 employees
  2. What sector does AstraZeneca operate in?

    AstraZeneca is in Pharmaceuticals
  3. Who are AstraZeneca's competitors?

    AstraZeneca's top competitors are Amgen, Genentech, TEVA Pharmaceuticals
  4. Who has AstraZeneca invested in?

    AstraZeneca's has invested in companies such as Innate Pharma, PhaseBio, Rani Therapeutics